A trial of ramucirumab plus paclitaxel combined therapy for elderly gastric cancer patients

Phase 2

Recruiting

• Conditions: refractory to first-line treatment; Advanced gastric cancer, Second-line treatment, Elderly gastric cancer

• Registration Number: JPRN-jRCT1031200158
• Lead Sponsor: Kunisaki Chikara

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

1. adenocarcinoma
2. unresectable or recurrent gastric cancer
3. PD after first-line treatment
4. No massive ascites
5. No metastasis for central nervus system
6. Sufficient oral intake
7. 70 years or more
8. ECOG performance status; grade 0, 1

Exclusion Criteria

1. Uncontrollable diabetes mellitus
2. VTE (DVT, PE)
3. Myocardial infaction
4. Cerebrovascular disease
5. GI tract bleeding within 3 months
6. GI tract perfooration
7. Uncotrollable hypertension
8. Patients with inadquate performance status

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety

Secondary Outcome Measures

Name	Time	Method
Response rate, Overall survival, Progression-free survival